Libya vs Pakistan: Cause of death, by non-communicable diseases, ages 60+, male
Libya
67.7%
in 2021
Pakistan
67.9%
in 2021
Libya rank
98th
Pakistan rank
97th
Cause of death, by non-communicable diseases, ages 60+, male over time
- Libya
- Pakistan
How they compare
Pakistan currently reports 67.9% against 67.7% in Libya, a difference of 0.2%.
The two have swapped places 1 time across 6 shared years of data; in 2000 it was Libya ahead.
Libya ranks 98th and Pakistan ranks 97th of 185 countries.
Libya has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Libya | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 88.8% | 78.9% | 9.9% | Libya |
| 2010s | 89.7% | 83.3% | 6.4% | Libya |
| 2020s | 73.6% | 70.0% | 3.6% | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 60+, male, Libya or Pakistan?
- Pakistan, at 67.9% against 67.7% in Libya as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 60+, male between Libya and Pakistan?
- 0.2%, with Pakistan ahead.
- How many years of comparable data are there for Libya and Pakistan?
- 6 years are reported by both, from 2000 to 2021.
- How do Libya and Pakistan rank globally for cause of death, by non-communicable diseases, ages 60+, male?
- Libya ranks 98th and Pakistan ranks 97th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 60+, male (% of total male deaths ages 60+). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of male deaths ages 60+ due to non-communicable diseases divided by number of all male deaths ages 60+, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.